Engene Therapeutics Inc. current report, 31 October 2023

Full document

Business Context and Reporting Period

enGene Holdings Inc. (formerly a shell company) completed its business combination with Forbion European Acquisition Corp. (FEAC) and enGene Inc. on October 31, 2023. enGene Inc. continues as the operating subsidiary. The transaction converted New enGene into a publicly traded biotechnology company focused on genetic medicines and its lead candidate, EG-70, for non-muscle-invasive bladder cancer.

New enGene shares and warrants began trading on Nasdaq on November 1, 2023 under the symbols ENGN and ENGNW. This 8-K primarily reports the transaction, related agreements, governance changes, and post-combination disclosure rather than a new quarterly earnings release.

Financial Metrics, Capitalization, and Liquidity

  • The PIPE financing issued 6,435,441 New enGene shares and 2,702,791 warrants for aggregate gross proceeds of $56.9 million.
  • Holders of 10,379,144 FEAC Class A shares elected redemption in connection with the business combination. The filing text does not provide a clear final cash balance, net proceeds after redemptions and expenses, or pro forma liquidity figure.
  • FEAC transferred the funds remaining in its trust account, subject to transaction deductions, to New enGene through a Canadian-dollar-denominated, non-interest-bearing demand promissory note. The filing does not provide the note’s principal amount.
  • The company’s inherited financing arrangements include a Loan and Security Agreement with Hercules Capital Inc.; the filing text does not provide current debt outstanding, interest rates, maturities, covenants, or borrowing capacity.
  • No current-period revenue, net loss, operating cash flow, free cash flow, gross margin, operating margin, or cash runway figures are presented in the supplied text. Historical enGene and pro forma financial statements are incorporated by reference or filed as exhibits.
  • New enGene has not paid dividends and does not expect to pay cash dividends for the foreseeable future.

Material Changes Versus the Prior Comparable Period

  • The principal change is structural: FEAC and enGene became wholly owned subsidiaries of New enGene, and New enGene ceased to be a shell company.
  • New enGene assumed FEAC’s warrants, generally exercisable at $11.50 per share, subject to adjustment.
  • The company completed the PIPE financing and issued additional shares and warrants under a non-redemption agreement.
  • New enGene adopted new articles, a 2023 Incentive Equity Plan, a Code of Business Conduct and Ethics, registration rights arrangements, and director and officer indemnification agreements.
  • Post-closing beneficial ownership included Forbion Growth at 31.9% of total voting power, Lumira Ventures affiliates at 14.4%, Forbion Capital Fund III at 14.2%, Biotechnology Value Fund affiliates at 13.2%, and Fonds de solidarité des travailleurs du Québec at 13.1%.

Guidance, Outlook, Commentary, and Risks

Management’s forward-looking assumptions include enrolling patients in the Phase 2 LEGEND trial, filing a Biologics License Application with the FDA in 2025 for EG-70 as a monotherapy for BCG-unresponsive non-muscle-invasive bladder cancer, retaining U.S. commercial rights, selectively partnering outside the United States, and developing additional applications through the DDX gene-delivery platform. These are assumptions and objectives, not reported guidance or guaranteed milestones.

Key risks include clinical-trial enrollment, safety and efficacy outcomes, regulatory approval, manufacturing and contract-manufacturer performance, competition, intellectual-property protection, reimbursement and market adoption, the need for additional capital, retention of key personnel, Nasdaq listing compliance, transaction-related disruption, litigation, and the company’s ability to maintain effective internal controls. The filing cautions that actual results may differ materially from forward-looking statements.

Important Facts for Investors to Verify

  • Final cash proceeds and remaining trust-account funds after redemptions, transaction expenses, and PIPE financing.
  • Current cash balance, projected cash runway, quarterly operating cash burn, and expected timing of any additional financing.
  • Outstanding principal, covenants, maturity dates, and security interests under the Hercules Capital facility and other debt instruments.
  • Final pro forma share count, warrant overhang, dilution from the PIPE, non-redemption issuance, options, and incentive equity plan.
  • LEGEND trial enrollment, clinical readouts, regulatory milestones, and whether the anticipated 2025 BLA filing remains achievable.
  • The company’s historical and pro forma revenue, net loss, operating cash flow, and margin information in the incorporated financial statements and Exhibit 99.1.
  • Nasdaq listing compliance, lock-up and registration-rights provisions, and the potential impact of concentrated ownership by major holders.